TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
LLY

Eli Lilly and Company

Healthcare · Drug Manufacturers - General

1,170.10$ +0.5% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Ratios

Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.

Tick rows to compare them in a chart (up to 4)

Ratios LLY
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Valuation
26.8 47.5 27.0 33.4 30.8 25.4 29.7 34.2 31.3 21.3 19.7 9.1 7.6 10.7 13.8 12.2 32.1 38.7 29.6 37.0 15.1 26.1 47.2 55.7 100.5 65.9 46.8
5.8 9.9 10.8 7.4 9.4 7.4 6.2 6.0 4.5 4.2 3.6 3.1 2.2 1.8 1.7 1.9 2.5 2.5 3.9 4.7 3.8 4.5 5.6 5.6 6.6 9.3 12.2 15.4 15.5 14.8
6.7 16.9 22.5 14.7 16.9 12.0 8.3 7.8 5.7 5.7 5.2 4.3 6.5 4.1 3.1 3.4 3.8 3.2 5.0 6.4 5.8 7.7 11.0 48.3 28.6 29.3 32.6 48.9 49.2 36.4
5.9 9.6 10.6 7.0 9.3 7.5 6.5 6.2 4.6 4.5 3.6 3.2 2.4 1.9 1.7 2.0 2.6 2.5 4.1 4.9 4.1 4.8 5.8 6.2 7.1 9.8 12.7 16.1 16.2 15.3
15.9 26.1 29.7 18.4 25.2 20.6 18.8 19.3 14.8 14.9 11.6 10.3 1,133.3 6.0 4.9 6.9 8.2 7.8 17.8 22.3 17.2 23.4 22.6 20.1 19.6 34.4 41.8 64.1 47.8 35.8
26.3 38.7 45.1 35.2 33.4 30.8 73.2 39.2 63.8 100.6 19.5 14.3 6.9 11.3 6.8 8.4 13.3 12.3 26.5 69.6 21.6 25.8 47.7 36.1 36.1 48.9 75.6 1,684.6 107.6
3.8% 2.6% 2.2% 2.8% 3.0% 3.2% 1.4% 2.6% 1.6% 1.0% 5.1% 7.0% 14.4% 8.9% 14.7% 12.0% 7.5% 8.1% 3.8% 1.4% 4.6% 3.9% 2.1% 2.8% 2.8% 2.0% 1.3% -0.6% 0.1% 0.9%
Margins
81.0% 82.0% 83.5% 83.4% 85.1% 81.3% 80.4% 78.7% 76.7% 76.3% 77.4% 77.2% 78.5% 80.6% 81.1% 79.1% 78.8% 78.8% 74.9% 74.8% 73.1% 77.7% 78.2% 78.8% 77.7% 74.2% 76.8% 79.2% 81.3% 83.8%
29.2% 30.5% 30.6% 33.6% 32.8% 32.3% 30.0% 27.8% 26.4% 24.9% 26.3% 25.8% 27.1% 29.2% 29.3% 26.0% 22.2% 24.0% 17.0% 18.0% 18.2% 21.3% 28.0% 26.9% 29.4% 28.0% 30.3% 31.6% 38.9% 45.6%
21.8% -4.8% 22.7% 27.2% 28.2% 24.1% 24.4% 20.4% 13.1% 13.5% 17.0% 15.8% -10.2% 19.8% 22.0% 17.9% 18.1% 20.3% 12.2% 12.1% 12.9% -1.0% 15.0% 37.3% 25.2% 19.7% 21.9% 15.4% 23.5% 31.7%
22.1% 25.5% 23.9% 20.9% 28.1% 24.1% 8.5% 15.4% 7.0% 4.2% 18.5% 21.9% 31.2% 15.9% 24.6% 22.8% 18.8% 20.1% 14.7% 6.7% 17.7% 17.3% 11.7% 15.6% 18.2% 19.0% 16.1% -9.2% 0.9% 13.8%
Returns
25.0% -8.3% 47.4% 54.3% 50.6% 39.1% 32.7% 26.2% 16.6% 18.3% 24.2% 21.9% -30.8% 45.5% 40.8% 32.1% 27.7% 26.6% 15.5% 16.5% 19.5% -1.8% 29.6% 319.1% 109.8% 62.2% 58.6% 48.6% 74.6% 77.8%
10.6% -3.1% 16.7% 21.2% 20.8% 16.9% 14.2% 11.8% 7.3% 8.1% 12.1% 11.0% -7.1% 15.8% 16.4% 12.9% 11.9% 13.3% 6.6% 6.8% 7.1% -0.5% 7.4% 21.2% 13.3% 11.4% 12.6% 8.2% 13.5% 18.3%
Balance Sheet & Debt
399 -1,720 -1,314 -3,459 -1,297 716 2,958 2,128 1,147 3,492 605 1,787 4,965 2,199 933 1,065 1,513 1,383 4,185 4,312 5,723 7,111 5,421 12,980 12,938 13,066 14,172 22,407 30,376 35,340
0.2 -0.6 -0.4 -0.9 -0.3 0.2 0.8 0.5 0.3 0.8 0.1 0.3 114.7 0.3 0.1 0.2 0.2 0.2 0.9 1.0 1.1 1.7 1.0 1.9 1.5 1.6 1.6 2.6 2.0 1.3
42.6% 36.9% 35.2% 39.1% 41.2% 43.2% 43.4% 45.0% 43.9% 43.9% 50.0% 50.4% 23.1% 34.7% 40.1% 40.2% 42.9% 50.0% 42.3% 41.0% 36.1% 25.8% 24.8% 6.6% 12.1% 18.4% 21.5% 16.8% 18.0% 23.6%
0.2 0.0 0.0 0.0 0.5 0.5 0.6 0.5 0.6 0.6 0.3 0.4 1.6 0.7 0.6 0.5 0.4 0.3 0.5 0.5 0.7 1.2 1.2 5.9 2.9 1.9 1.5 2.3 2.4 1.6
Per Share
1.36 -0.34 1.87 2.46 2.79 2.55 2.50 2.37 1.66 1.81 2.45 2.71 -1.89 3.94 4.58 3.90 3.57 4.19 2.15 2.18 2.49 -0.19 3.13 8.69 6.47 5.85 6.57 5.80 11.71 22.98
6.26 7.07 8.24 9.04 9.91 10.59 10.23 11.65 12.71 13.39 14.44 17.08 18.61 19.88 20.87 21.80 19.72 20.70 17.66 18.06 19.28 18.99 20.79 23.31 25.65 29.69 30.04 37.78 49.82 72.58
5.46 4.11 3.95 4.53 5.52 6.52 7.64 9.04 10.01 9.87 10.10 12.38 6.15 8.67 11.23 12.16 12.88 15.79 13.84 13.18 12.72 11.02 10.55 2.72 5.90 9.42 11.21 11.93 15.70 29.55
1.39 1.80 1.97 1.89 2.79 2.55 0.87 1.80 0.89 0.56 2.67 3.73 5.80 3.17 5.13 4.97 3.72 4.16 2.60 1.21 3.41 3.28 2.42 3.64 4.67 5.65 4.84 -3.49 0.46 9.99

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?